Nuvalent Completes $135 Million Series B Financing To Advance Portfolio Of Novel Precisely Targeted Kinase Inhibitors For Treatment-Resistant Cancers
Amount Raised
$135 Million
Round Type
Series B
CambridgeBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalDescription
Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital. Andrew Hack, M.D., Ph.D., a Managing Director of Bain Capital Life Sciences, will join the Nuvalent Board of Directors.
Quick answer
Nuvalent raised $135 Million in a Series B round, dated May 11, 2021. Nuvalent is based in Cambridge, Massachusetts, United States.
- How much did Nuvalent raise?
- Nuvalent raised $135 Million in a Series B round on May 11, 2021.
- What does Nuvalent do?
- Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.
- Where is Nuvalent based and how big is it?
- Nuvalent is based in Cambridge, Massachusetts, United States. Fundz records about 170 employees.
- Who are the decision-makers at Nuvalent?
- Fundz holds 2 contacts at Nuvalent. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Nuvalent that raised within 45 days of this round, from Fundz verified event records.
- Arbutus raised $81M on June 23, 2021.
- Zevra Therapeutics, Inc. raised $39M on June 22, 2021.
- Os Therapies raised $6M (Series A) on April 20, 2021.
- Korsana Biosciences raised $18M on June 17, 2021.
- BriaCell Therapeutics Corp. raised $27M on June 15, 2021.
- Ajax Therapeutics, Inc. raised $37M on June 1, 2021.
Who to call at Nuvalent, and when
A new round usually means Nuvalent is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nuvalent raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuvalent, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuvalent. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuvalent raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNuvalent raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.